Cargando…

Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era

SIMPLE SUMMARY: The genetic landscape of diffuse large B-cell lymphoma (DLBCL) is heterogenous. So far, detailed studies about TP53 mutations in DLBCL treated with anti-CD19 chimeric antigen receptor T-cell (CAR T cells) therapy are still missing. Chemotherapy resistance is one of the challenges in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Porpaczy, Edit, Wohlfarth, Philipp, Königsbrügge, Oliver, Rabitsch, Werner, Skrabs, Cathrin, Staber, Philipp, Worel, Nina, Müllauer, Leonhard, Simonitsch-Klupp, Ingrid, Kornauth, Christoph, Rohrbeck, Johannes, Jaeger, Ulrich, Schiefer, Ana-Iris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616128/ https://www.ncbi.nlm.nih.gov/pubmed/34830747 http://dx.doi.org/10.3390/cancers13225592

Ejemplares similares

Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study
por: Schiefer, Ana-Iris, et al.
Publicado: (2015)

The frequency of differentiated CD3(+)CD27(-)CD28(-) T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma
por: Worel, Nina, et al.
Publicado: (2023)

Ultra-early response assessment in lymphoma treatment: [(18)F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment
por: Mayerhoefer, Marius E., et al.
Publicado: (2018)

CD19 CAR T-cell infusion during severe COVID-19 acute respiratory distress syndrome in large B-cell lymphoma
por: Buchtele, Nina, et al.
Publicado: (2022)

RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients
por: Berzaczy, Dominik, et al.
Publicado: (2019)

Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas
por: Wagner, Sandro M., et al.
Publicado: (2020)

Chimeric antigen receptor T‑cell therapy—a hematological success story
por: Wohlfarth, Philipp, et al.
Publicado: (2018)

CXCR4 PET imaging of mantle cell lymphoma using [(68)Ga]Pentixafor: comparison with [(18)F]FDG-PET
por: Mayerhoefer, Marius E., et al.
Publicado: (2021)

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
por: Gisslinger, H, et al.
Publicado: (2016)

Erratum: Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
por: Gisslinger, H, et al.
Publicado: (2017)

Transformed mucosa‐associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction‐based clonality analysis
por: Kiesewetter, Barbara, et al.
Publicado: (2019)

Cannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation
por: Freund, Patricia, et al.
Publicado: (2016)

Antigen-Specific Immunoadsorption With the Glycosorb® ABO Immunoadsorption System as a Novel Treatment Modality in Pure Red Cell Aplasia Following Major and Bidirectional ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation
por: Handisurya, Ammon, et al.
Publicado: (2020)

T-Cell Large Granular Lymphocyte Leukemia: An Interdisciplinary Issue?
por: Schreiber, Johanna, et al.
Publicado: (2022)

Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation
por: Merkel, Olaf, et al.
Publicado: (2015)

Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
por: Heinemann, Tim, et al.
Publicado: (2022)

CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope
por: Hopfinger, Georg, et al.
Publicado: (2019)

The assessment of platelet function by thromboelastometry as a point‐of‐care test to guide Intercept‐treated platelet support in hemato‐oncological patients and hematopoietic stem cell transplantation recipients
por: Leitner, Gerda C., et al.
Publicado: (2020)

Lymphoma in Danon disease with chronic rhabdomyolysis treated with EPOCH-R: A case report
por: Porpaczy, Edit, et al.
Publicado: (2016)

Systemic mastocytosis associated with chronic myelomonocytic leukemia and xanthogranuloma
por: Tschandl, Philipp, et al.
Publicado: (2012)

Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome
por: Janik, Stefan, et al.
Publicado: (2018)

Follistatin impacts Tumor Angiogenesis and Outcome in Thymic Epithelial Tumors
por: Janik, Stefan, et al.
Publicado: (2019)

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
por: Kornauth, Christoph, et al.
Publicado: (2022)

Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis
por: Rabitsch, W., et al.
Publicado: (2016)

Containment of a traceable COVID-19 outbreak among healthcare workers at a hematopoietic stem cell transplantation unit
por: Buchtele, N., et al.
Publicado: (2020)

A bi‐centric experience of extracorporeal carbon dioxide removal (ECCO(2)R) for acute hypercapnic respiratory failure following allogeneic hematopoietic stem cell transplantation
por: Wohlfarth, Philipp, et al.
Publicado: (2021)

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
por: Greiner, Georg, et al.
Publicado: (2020)

Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis
por: Berger, Daniela, et al.
Publicado: (2021)

Autologous hematopoietic stem cell transplantation with concomitant SARS-CoV-2 infection
por: Knaus, Hanna A., et al.
Publicado: (2021)

Critically ill patients with cancer: chances and limitations of intensive care medicine—a narrative review
por: Schellongowski, Peter, et al.
Publicado: (2016)

Myelomonocytic Skewing In Vitro Discriminates Subgroups of Patients with Myelofibrosis with A Different Phenotype, A Different Mutational Profile and Different Prognosis
por: Geissler, Klaus, et al.
Publicado: (2020)

Metabolic drug survey highlights cancer cell dependencies and vulnerabilities
por: Pemovska, Tea, et al.
Publicado: (2021)

Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling
por: Hassler, Melanie R., et al.
Publicado: (2016)

Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure
por: Wohlfarth, Philipp, et al.
Publicado: (2014)

Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients
por: Mayerhoefer, Marius E., et al.
Publicado: (2016)

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
por: Kornauth, Christoph, et al.
Publicado: (2021)

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study
por: Snijder, Berend, et al.
Publicado: (2017)

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib
por: Kazianka, L, et al.
Publicado: (2017)

SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria: Findings of a multicentric nationwide study
por: Berger, Julia M., et al.
Publicado: (2022)

Expression of RAGE and HMGB1 in Thymic Epithelial Tumors, Thymic Hyperplasia and Regular Thymic Morphology
por: Moser, Bernhard, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i6mnqphm3a4tqh7gb2v585ta8n